GlassScriptPhysician profile
Megan A Wetherbee
NPI 1659850410
$4,219.65
in general payments reported to CMS, 2019-2025
37 companies · $856 in 2025
The $856 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,091 · 2022: $670 · 2023: $1,216 · 2024: $387 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,127 · Travel and Lodging: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,126.85 |
| Travel and Lodging | $331.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,300.94 | 2021-2025 | Cd Horizon Spinal System, Anteralign Spinal System With Titan Nanolock Surface Technology, Unid_pass |
| Novartis Pharmaceuticals Corporation | $362.65 | 2021-2025 | |
| Stryker Corporation | $279.82 | 2021-2022 | |
| Abbvie INC. | $224.81 | 2021-2025 | |
| Boston Scientific Corporation | $200.84 | 2025 | Wavewriter Alpha Prime 16, Intracept |
| Ucb, INC. | $184.15 | 2021-2023 | Nayzilam, Briviact, Fintepla |
| Eisai INC. | $182.70 | 2021-2023 | |
| Merz Pharmaceuticals, LLC | $133.28 | 2021-2022 | |
| Tanabe Pharma America, INC. | $121.05 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $120.81 | 2022-2024 | |
| Harmony Biosciences LLC | $114.83 | 2022-2023 | Wakix |
| Alexion Pharmaceuticals, INC. | $88.63 | 2021-2024 | Ultomiris |
| Emd Serono, INC. | $83.99 | 2022-2024 | Mavenclad |
| Acorda Therapeutics, INC | $77.61 | 2021-2022 | |
| Octapharma USA, INC. | $71.86 | 2023 | Panzyga |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $69.64 | 2021 | |
| Amneal Pharmaceuticals LLC | $56.33 | 2022-2023 | Rytary |
| Lilly USA, LLC | $54.37 | 2021-2023 | Amyvid, Reyvow, Emgality |
| Depuy Synthes Sales INC. | $43.10 | 2025 | Symphony |
| Sk Life Science, INC. | $42.95 | 2021 | |
| Alnylam Pharmaceuticals INC. | $38.44 | 2021-2023 | Amvuttra |
| Tg Therapeutics, INC. | $35.98 | 2023-2024 | |
| Nevro Corp. | $28.07 | 2022 | |
| Horizon Therapeutics Plc | $26.20 | 2023 | Uplizna |
| Grifols USA, LLC | $25.29 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $24.50 | 2023 | Relyvrio |
| Ipsen Biopharmaceuticals, INC | $24.45 | 2023 | Dysport |
| Grt US Holding, INC. | $23.97 | 2022 | |
| Argenx US, INC. | $23.84 | 2023 | Vyvgart |
| Ge Healthcare | $23.01 | 2023 | |
| Acadia Pharmaceuticals INC | $21.69 | 2023 | Daybue |
| Ultragenyx Pharmaceutical INC. | $21.67 | 2022 | |
| Genentech, INC. | $21.21 | 2024 | Ocrevus |
| Teva Pharmaceuticals USA, INC. | $20.64 | 2023 | Austedo Xr |
| Avadel Cns Pharmaceuticals, LLC | $15.70 | 2023 | Lumryz |
| Livanova USA, INC. | $15.50 | 2021 | |
| Biogen, INC. | $15.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Wetherbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.